Several cutting edge behavioral interventions are being used in clinical trials for prevention of relapse to smoking, including cognitive remediation approaches, mindfulness practice and neurofeedback of brain activity during active craving.
Research from the Massachusetts General Hospital Schizophrenia Program and others has shown that, with appropriate treatment, smokers with schizophrenia can successfully quit smoking without worsening of their symptoms of schizophrenia. This work has recently been highlighted in clinical practice guidelines recommending that all people with schizophrenia spectrum disorders who smoke and want to quit be offered bupropion with or without nicotine replacement therapy along with behavioral support.
We offer a range of smoking cessation services, both routine and through clinical trials.
The program is not limited to patients in our psychiatric care at Mass General, it’s also available to the public as a health resource through our research program. Read more information about our program.
Proto magazine stakes its ground on medicine's leading edge, reporting back from the frontiers of research and practice - exploring breakthroughs, dissecting controversies and opening a forum for informed debate.
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care
Discover what makes Massachusetts General Hospital not just one of the best places to receive patient care but also one of the best places to work.